## **ICMJE DISCLOSURE FORM**

Date:		-	6/3/2022			
Your Name:		<u>-</u>	M de Boer			
Manuscript Title:		_	De adviezen voor de medicamenteuze behandeling van COVID-19 in de tweede lijn: een update			
Man	uscript Number (if k	nown):	Click or tap here to enter text.			
content of your manuscript. "Relat affected by the content of the manindicate a bias. If you are in doubt			eask you to disclose all relationships/activities/interests listed below that are related to the ted" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily about whether to list a relationship/activity/interest, it is preferable that you do so.			
-	emiology of hyperter medication is not me	-	•	acturers of antihypertensive medication, even if		
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.						
			entities with whom you have this hip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	De forr	Time frame: Since the initial planning one matie van de nieuwe guideline en de teuning van de adviezen worden mogelijk gemaakt door een grant van	Click the tab key to add additional rows.		
	Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	⊠ Nor	ne			
3	Royalties or licenses	⊠ No	one			

			cations/Comments (e.g., if payments were so you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	□ None  □ Dagelijks Bestuur SWAB	
7	Support for attending meetings and/or travel	None None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options		None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Please place an "X" next to the following statement to indicate your agreement:				